Below are the most recent publications written about "Product Surveillance, Postmarketing" by people in Profiles.
-
Huybrechts KF, Kulldorff M, Hernández-Díaz S, Bateman BT, Zhu Y, Mogun H, Wang SV. Active Surveillance of the Safety of Medications Used During Pregnancy. Am J Epidemiol. 2021 06 01; 190(6):1159-1168.
-
Colombo A, Chandrasekhar J, Aquino M, Ong TK, Sartori S, Baber U, Lee M, Iniguez A, Hajek P, Borisov B, Atzev B, Den Heijer P, Coufal Z, Hudec M, Mates M, Snyder C, Moalem K, Morrell D, Elmore F, Rowland S, Mehran R. Safety and efficacy of the COMBO bio-engineered stent in an all-comer PCI cohort: 1-Year final clinical outcomes from the MASCOT post-marketing registry. Int J Cardiol. 2019 05 15; 283:67-72.
-
de Winter RJ, Chandrasekhar J, Kalkman DN, Aquino MB, Woudstra P, Beijk MA, Sartori S, Baber U, Tijssen JG, Koch KT, Dangas GD, Colombo A, Mehran R. 1-Year Clinical Outcomes of All-Comer Patients Treated With the Dual-Therapy COMBO Stent: Primary Results of the COMBO Collaboration. JACC Cardiovasc Interv. 2018 10 08; 11(19):1969-1978.
-
Wang SV, Jin Y, Fireman B, Gruber S, He M, Wyss R, Shin H, Ma Y, Keeton S, Karami S, Major JM, Schneeweiss S, Gagne JJ. Relative Performance of Propensity Score Matching Strategies for Subgroup Analyses. Am J Epidemiol. 2018 08 01; 187(8):1799-1807.
-
Mariette X, Förger F, Abraham B, Flynn AD, Moltó A, Flipo RM, van Tubergen A, Shaughnessy L, Simpson J, Teil M, Helmer E, Wang M, Chakravarty EF. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018 02; 77(2):228-233.
-
Wang SV, Schneeweiss S, Maclure M, Gagne JJ. "First-wave" bias when conducting active safety monitoring of newly marketed medications with outcome-indexed self-controlled designs. Am J Epidemiol. 2014 Sep 15; 180(6):636-44.
-
Gagne JJ, Wang SV, Rassen JA, Schneeweiss S. A modular, prospective, semi-automated drug safety monitoring system for use in a distributed data environment. Pharmacoepidemiol Drug Saf. 2014 Jun; 23(6):619-27.
-
Thadani U. Should ranolazine be used for all patients with ischemic heart disease or only for symptomatic patients with stable angina or for those with refractory angina pectoris? A critical appraisal. Expert Opin Pharmacother. 2012 Dec; 13(17):2555-63.
-
Diehl DL, Tierney WM, Adler DG, Conway JD, Farraye FA, Kantsevoy SV, Kaul V, Kethu SR, Kwon RS, Mamula P, Pedrosa MC, Rodriguez SA. The role of the U.S. Food and Drug Administration in device evaluation and monitoring. Gastrointest Endosc. 2010 Jul; 72(1):5-10.
-
Block SL, Brown DR, Chatterjee A, Gold MA, Sings HL, Meibohm A, Dana A, Haupt RM, Barr E, Tamms GM, Zhou H, Reisinger KS. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine. Pediatr Infect Dis J. 2010 Feb; 29(2):95-101.